Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07165938 · ClinicalTrials.gov registry record

Genetics of Neonatal Encephalopathy and Related Disorders

A clinical trial of Neonatal Encephalopathy and Hypoxic Ischaemic Encephalopathy (HIE), sponsored by Boston Children's Hospital.

Recruiting
Registry status
300
Enrollment target
1
Study location

NCT07165938: Recruiting study of Neonatal Encephalopathy and Hypoxic Ischaemic Encephalopathy (HIE), sponsored by Boston Children's Hospital.

NCT07165938 is a study of Neonatal Encephalopathy and Hypoxic Ischaemic Encephalopathy (HIE) that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 300 participants, above the 87-participant average among 6 other Neonatal Encephalopathy trials with a reported enrollment target (245% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07165938, a study of Neonatal Encephalopathy and Hypoxic Ischaemic Encephalopathy (HIE), is actively recruiting participants, sponsored by Boston Children's Hospital.

RECRUITING
Registry status
300 participants
Enrollment target
1
Study location

Study Summary

Investigators at Boston Children's Hospital are conducting research in order to better understand the genetic factors which may contribute to neonatal encephalopathy (NE) and related disorders. These findings may help explain the broad spectrum of clinical features and outcomes seen in individuals with a history of NE.

Primary Outcome

The diagnostic yield of genomic sequencing will be calculated as the percentage of enrolled participants with NE who receive a genetic diagnosis.

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2026-02-04
Est. Completion 2035-09
Boston Children's Hospital

462 total trials

What NCT07165938 shows while recruiting

NCT07165938 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 87-participant average among 6 other Neonatal Encephalopathy trials with a reported enrollment target (245% higher).

The record links to 2 conditions, with Neonatal Encephalopathy appearing as the primary indexed condition, and to 0 interventions.

NCT07165938 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07165938 about?

NCT07165938 is a clinical study titled "Genetics of Neonatal Encephalopathy and Related Disorders". Investigators at Boston Children's Hospital are conducting research in order to better understand the genetic factors which may contribute to neonatal encephalopathy (NE) and related disorders. These findings may help explain the broad spectrum of clinical features and outcomes seen in individuals w...

What is the current status of trial NCT07165938?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2026-02-04. Estimated completion is 2035-09.

What conditions does trial NCT07165938 study?

This clinical trial studies the following conditions: Neonatal Encephalopathy, Hypoxic Ischaemic Encephalopathy (HIE).

Who is sponsoring clinical trial NCT07165938?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07165938 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neonatal Encephalopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07165938, the US trial registry maintained by the National Library of Medicine. NCT07165938 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.